Serum biomarkers for monitoring response to tuberculosis treatment: an assessment of the effect of different covariates among slow and fast treatment responders

References

• Beia, T., Kielmann, K., and Diaconu, K., 2021. Changing men or changing health systems? A scoping review of interventions, services and programmes targeting men’s health in sub-Saharan Africa. International journal for equity in health, 20 (1), 1–16.
   PubMed Web of Science ®Google Scholar
• Blauenfeldt, T., et al., 2018. Interplay of DDP4 and IP-10 as a potential mechanism for cell recruitment to tuberculosis lesions. Frontiers in microbiology, 9 (JUL), 1–11.
   PubMedGoogle Scholar
• Boni, F.G., et al., 2022. Cytokine storm in tuberculosis and IL-6 involvement. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 97 (August 2021), 105166.
   PubMedGoogle Scholar
• Chegou, N.N., et al., 2016. Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB. Thorax, 71 (9), 785–794.
   PubMed Web of Science ®Google Scholar
• Clifford, V., et al., 2015. ‘Cytokines for monitoring anti-tuberculous therapy: a systematic review’, Tuberculosis, 95 (3), 217–228.
   Google Scholar
• Curry, F. J., 2006. International standards for tuberculosis care (ISTC). The Hague: Tuberculosis Coalition for Technical Assistance.
   Google Scholar
• Efriyani, Y.I., et al., 2021. IP-10 as a non sputum biomarker in TB treatment monitoring. Majalah kedokteran bandung, 53 (1).
   Google Scholar
• Harries, A., and Kumar, A., 2018. Challenges and progress with diagnosing pulmonary tuberculosis in low- and middle-income countries. Diagnostics, 8 (4), 78.
   Web of Science ®Google Scholar
• Heyckendorf, J., et al., 2022. Tuberculosis treatment monitoring and outcome measures: new interest and new strategies. Clinical microbiology reviews, 35 (3), e0022721.
   PubMed Web of Science ®Google Scholar
• Jacobs, R., et al., 2016. Identification of novel host biomarkers in plasma as candidates for the immunodiagnosis of tuberculosis disease and monitoring of tuberculosis treatment response. Oncotarget, 7 (36), 57581–57592.
   PubMedGoogle Scholar
• Johnson, J.L., et al., 2009. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. American journal of respiratory and critical care medicine, 180 (6), 558–563.
   PubMed Web of Science ®Google Scholar
• Khader, S. a., et al., 2005. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. Journal of immunology (Baltimore, Md. : 1950), 175 (2), 788–795.
   PubMed Web of Science ®Google Scholar
• Khan, N., et al., 2017. T-cell exhaustion in tuberculosis: pitfalls and prospects. Critical reviews in microbiology, 43 (2), 133–141.
   PubMed Web of Science ®Google Scholar
• Kumar, N.P., et al., 2016. Circulating angiogenic factors as biomarkers of disease severity and bacterial burden in pulmonary tuberculosis. PLoS one, 11 (1), e0146318.
   PubMed Web of Science ®Google Scholar
• Laniado-Laborín, R., 2017. Clinical challenges in the era of multiple and extensively drug-resistant tuberculosis. Revista panamericana de salud pública, 41, e167.
   PubMed Web of Science ®Google Scholar
• Malherbe, S.T., et al., 2020. Quantitative 18F-FDG PET-CT scan characteristics correlate with tuberculosis treatment response. EJNMMI research, 10 (1), 8.
   PubMed Web of Science ®Google Scholar
• Nagabhushanam, V., et al., 2003. Innate Inhibition of adaptive immunity: mycobacterium tuberculosis -induced IL-6 inhibits macrophage responses to IFN-γ. Journal of immunology (Baltimore, Md. : 1950), 171 (9), 4750–4757.
   PubMed Web of Science ®Google Scholar
• Nosik, M., et al., 2021. Dynamics of plasmatic levels of pro-and anti-inflammatory cytokines in hiv-infected individuals with m. Tuberculosis co-infection. Microorganisms, 9 (11), 2291.
   PubMed Web of Science ®Google Scholar
• Okamoto Yoshida, Y., et al., 2010. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. Journal of immunology (Baltimore, Md. : 1950), 184 (8), 4414–4422.
   PubMed Web of Science ®Google Scholar
• Polena, H., et al., 2016. ‘Mycobacterium tuberculosis exploits the formation of new blood vessels for its dissemination’, Scientific Reports, 6 (August), 33162.
   Google Scholar
• Ronacher, K., et al., 2019. ‘Distinct serum biosignatures are associated with different tuberculosis treatment outcomes’, Tuberculosis, 118 (September), 101859.
   Google Scholar
• Saghazadeh, A., and Rezaei, N., 2022. Vascular endothelial growth factor levels in tuberculosis: a systematic review and metaanalysis. PLoS one, 17 (5), e0268543.
   PubMedGoogle Scholar
• Saunders, B.M., et al., 2000. Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection. Infection and immunity, 68 (6), 3322–3326.
   PubMed Web of Science ®Google Scholar
• Sigal, G. B., et al., 2017. ‘Biomarkers of Tuberculosis severity and treatment effect: a directed screen of 70 host markers in a randomized clinical trial’, EBioMedicine, 25, 112–121.
   Google Scholar
• Suwara, M. I., et al., 2014. ‘IL-1a released from damaged epithelial cells is sufficient and essential to trigger inflammatory responses in human lung fibroblasts’, Mucosal Immunology, 7(3), 684–693.
   Google Scholar
• Verma, N.D., et al., 2014. Interleukin-12 (IL-12p70) promotes induction of highly potent Th1-like CD4 + CD25+ T regulatory cells that inhibit allograft rejection in unmodified recipients. Frontiers in immunology, 5 (MAY), 14–16.
   Google Scholar
• Wallis, R.S., et al., 2013. Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model. PLoS one., 8 (8), e71116.
   PubMed Web of Science ®Google Scholar
• Walzl, G., et al., 2008. Biomarkers for TB treatment response : Challenges and future strategies Biomarkers for TB treatment response : Challenges and future strategies, (August).
   Google Scholar
• Walzl, G., et al., 2011. Immunological biomarkers of tuberculosis’, Nature reviews. Immunology, 11(5), 343–354.
   Google Scholar
• Wei, M., et al., 2015. Regulation network of serum cytokines induced by tuberculosis-specific antigens reveals biomarkers for tuberculosis diagnosis. Genetics and molecular research: GMR, 14 (4), 17182–17192.
   PubMed Web of Science ®Google Scholar
• Wong, E.A., et al., 2020. IL-10 Impairs local immune response in lung granulomas and lymph nodes during early Mycobacterium tuberculosis infection. Journal of immunology (Baltimore, Md. : 1950), 204 (3), 644–659.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2010. Treatment of tuberculosis guidelines.
   Google Scholar
• World Health Organization. 2022. Global Tuberculosis report. Geneva: World Health Organization.
   Google Scholar
• Zhao, Y., et al., 2018. ‘IP-10 and RANTES as biomarkers for pulmonary tuberculosis diagnosis and monitoring’, Tuberculosis. Elsevier, 111 (May), 45–53.
   Google Scholar
• Zimmer, A.J., et al., 2022. Biomarkers that correlate with active pulmonary tuberculosis treatment response: a systematic review and meta-analysis. Journal of clinical microbiology, 60 (2), e0185921.
   Web of Science ®Google Scholar